Circassia

We're a specialty biopharmaceutical company developing novel immunotherapies for allergy including cat, grass, ragweed & house dust mite.

Circassia is a specialty biopharmaceutical company focused on allergy and respiratory disease. Our growing commercial organization promotes our innovative asthma management products directly to specialist physicians, and we have a broad pipeline of allergy, asthma and COPD treatments in development. Our novel, market-leading NIOX products are used by allergy / asthma specialists around the world to aid asthma diagnosis and management. We sell NIOX direct in the United States and Germany, and plan to expand our geographical presence in the near future. Our NIOX products are also supplied in many other countries through our international network of partners. Our development pipeline includes a range of treatments for allergy. Our immunotherapy targeting cat allergy has recently completed a phase III study, and is the first in the new class of treatments, Synthetic Peptide Immuno-Regulatory Epitopes (SPIREs). Three of our other SPIREs, targeting house dust mite, ragweed and grass allergies, have completed clinical proof-of-concept phase IIb studies. Our lead asthma product targets substitution of GSK’s Flixotide pMDI, and was recently approved in the UK under the European decentralized procedure. We expect two further filings for regulatory approval by the end of 2017, for products targeting direct substitution of Serevent pMDI and Seretide pMDI. We are also developing a number of novel treatments for chronic obstructive pulmonary disease, including an inhaled fixed-dose ‘triple’ combination of corticosteroid, long-acting beta agonist and long-acting muscarinic antagonist.